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Abstract
Background: Sentinel lymph node (SLN) biopsy is performed at many institutions and is considered a
standard of care in the management of cutaneous melanoma. The discriminatory immunostaining pattern
with the 'MCW Melanoma Cocktail' (a mixture of MART-1 {1:500}, Melan- A {1:100}, and Tyrosinase
{1:50} monoclonal antibodies) allows intraoperative immunocytochemical evaluation of imprint smears of
SLNs for melanoma metastases. Cohesive cells of benign capsular melanocytic nevi that were also
immunoreactive with the cocktail do not exfoliate easily for imprint smear detection.
Methods: We prospectively evaluated 73 lymph nodes (70 SLN & 3 non-SLN) from 41 cases (mean 1.8,
1 to 4 SLNs/case) of cutaneous melanoma using a rapid 17-minute immunostaining previously published
protocol. The results were compared with permanent sections also immunostained with 'the cocktail'.
Results: 19.5%, 8/41 cases (12%, 9/73 lymph nodes) were positive for melanoma metastases on
permanent sections immunostained with the 'MCW melanoma cocktail'. Melanoma metastases in 87.5%
(7/8) of these cases were also detected in rapidly immunostained imprint smears, with 100% specificity and
90% sensitivity. None of the 7 SLNs from 7 cases with capsular nevi showed false positive results.
Conclusion: Melanoma metastases could be detected in imprint smears immunostained with 'MCW
Melanoma Cocktail' utilizing a rapid intraoperative protocol. The cohesive cells of the capsular nevi do not
readily exfoliate and do not lead to false positive interpretation. In a majority of positive cases, a regional
lymphadenectomy could have been completed during the same surgery for SLN biopsy and wide excision
of primary melanoma site, potentially eliminating the need for an additional surgery.
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Skin melanoma is the sixth most common cancer in US
with an increasing rate in men [1]. Due to rapidly progres-
sive nature of the disease, aggressive definitive therapy at
earliest stage is the best option. Because of associated high
morbidity and the scarcity of follow up studies evaluating
its survival benefits, the role of routine performance of
regional lymphadenectomy in all cases irrespective of
their status is controversial [2,3]. An international multi-
centre randomized prospective trial by the Intergroup
Melanoma Surgical Program, reported that regional node
dissection offers increased survival in subset of patients
with nodal metastases (60 years of age or younger with
intermediate-thickness nonulcerative melanomas) [4].
Sentinel lymph node (SLN) biopsy is recommended as a
tool to identify this subset of patients, who could then
undergo elective regional lymph node dissection [5]. The
negative status of SLN for melanoma metastases correlates
closely with the negative status of regional lymph nodes
[6].
Thus, prevailing evidence supports the evaluation of SLN
for melanoma metastases as the standard of care to iden-
tify subset of patients with metastases in cutaneous
melanoma. It is practiced throughout the academic cent-
ers as well as regional and community hospitals with
increasing frequency [2-22].
Although, it is beneficial to complete a regional lym-
phadenectomy during the same initial surgical procedure
for 'SLN biopsy with wide excision of primary melanoma',
currently the patient has to undergo regional lym-
phadenectomy at later date under separate anesthesia, if
SLNs are positive for melanoma metastases. In the current
situation the results can not be obtained intraoperatively.
Preoperative or intraoperative evaluation technique
would result in a cost saving with numerous other benefits
[23-31].
Frozen-section examination (with or without immuno-
histochemical evaluation) and the morphological evalua-
tion of imprint cytology smears are some of the methods
evaluated for the intraoperative examination of SLN in
cutaneous melanoma. However, the studies evaluating
these methods did not demonstrate encouraging results
[25-31], primarily due to lack of adequate sensitivity.
The 'MCW Melanoma Cocktail' (a mixture of MART-1
{1:500}, Melan- A {1:100}, and Tyrosinase {1:50} mon-
oclonal antibodies) demonstrated an excellent discrimi-
natory immunostaining pattern [32,33]. This has
facilitated rapid intraoperative evaluation of SLNs for
melanoma micrometastases by examining imprint smears
of SLNs immunostained with the cocktail [34,35]. This
was not previously possible with conventional immu-
nomarkers such as the S-100 protein and HMB45 due to
significant interference caused by non-melanoma cells
such as dendritic cells and mast cells resulting in a high
noise to signal ratio [33,36].
In this article we report the results on a series of cutaneous
melanoma cases studied with rapid intraoperative evalua-
tion of SLN for melanoma metastases employing imprint
smears immunostained with 'MCW melanoma cocktail'.
Materials and methods
Patients
73 lymph nodes (70 SLNs & 3 non-SLNs) from 41 cases
with clinically localized cutaneous melanoma were stud-
ied prospectively under the IRB approved protocol. The
demographics are shown in table 1. As this was as a
research study, intraoperative decisions for the continua-
tion of a regional lymphadenectomy were not executed
regardless of positive results with immunostained imprint
smear(s) of SLNs. This was explained to the patients par-
ticipating in the study as a component of the informed
consent.
All patients underwent mappings and biopsies of SLNs
with a wide excision of the primary site at Froedert Memo-
rial Lutheran Hospital/Medical College of Wisconsin, Mil-
waukee, WI. A standard surgical protocol was used to
identify the SLN [37]. The tumor bed was injected preop-
eratively with technetium sulfur colloid. Additionally,
dermis around the lesion was injected intraoperatively
with isosulfan blue dye to facilitate the visual identifica-
tion of the SLN [37]. The SLNs were harvested and sub-
mitted fresh without any fixative to pathology for
intraoperative and permanent section evaluation.
Pathologic examination (Figure 1)
The excised lymph nodes were transected perpendicular to
the long axis and processed to make imprint smears as
previously reported [35]. The imprint smears were immu-
nostained with the 'MCW melanoma cocktail' using either
a manual method or the Dako® Autostainer with a rapid
17-minute immunostaining protocol utilizing the Dako
EnvisionTM+ System which does not contain avidin-
biotin [35]. One smear of a previously prepared positive
control from a known melanoma tumor and processed
similar to test smears [35] was also immunostained with
each staining batch.
The immunostained imprint smears were examined and
interpreted as positive, indeterminate, or negative for
melanoma metastases. The time required to go from prep-
aration of imprint smears to evaluation of immunos-
tained smears was also tracked. Based on the algorithm for
intraoperative decision, indeterminate interpretationsPage 2 of 9
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negative for statistical analysis.
After imprint smear preparation, the slices of SLNs were
fixed in 10% formalin and processed in the usual manner
for paraffin embedding. Three FPTS levels, each cut at
200-μm intervals were stained with hematoxylin and
eosin (H&E). The levels adjacent to the middle H&E sec-
tion were immunostained with 'MCW melanoma cock-
tail' using the avidin-biotin-peroxidase complex (ABC)
method described previously [33].
The results were considered positive for melanoma metas-
tases if cytoplasmic immunoreactivity was detected in cell
clusters or individual cells that demonstrated morpho-
logic features of melanoma tumor cells. When discrepan-
cies existed between immunostained imprint smears and
the immunostained FPTS, the slides were reviewed by
another pathologist in an attempt to determine the cause
of the discrepancy and to arrive at a conclusion (Table 2).
Results
The time required for completing the entire procedure
from preparation of imprint smears to evaluation of
immunostained smears ranged from 24 to 45 (mean, 35)
minutes and depended on the size-number of SLNs.
At the case level, melanoma metastases were identified in
lymph nodes of 19.5% (8 out of 41) of patients by the
immunohistochemical evaluation of FPTS. 87.5% (7 out
of 8) of these cases showed metastases in imprint smears
immunostained rapidly with the 'MCW melanoma cock-
tail', potentially saving a second surgery in all these cases.
The test demonstrated a sensitivity of 89%, a specificity of
100%, the negative predictive value of 97%, and the pos-
itive predictive value of 100%.
At the lymph node level, 12% (9/73) nodes were positive
for melanoma metastases with immunostained FPTS. Of
these, 89% (8/9) showed melanoma metastases in intra-
operatively immunostained imprint smears utilizing the
cocktail demonstrating a sensitivity of 90%, a specificity
of 100%, the negative predictive value of 99%, and the
positive predictive value of 100%).
The immunostained tumor cells of melanoma metastases
(Figure 2) showed a high nuclear to cytoplasmic ratio with
non-granular cytoplasmic staining around the nuclei facil-
itating easy evaluation of nuclear details [35]. All 7 SLNs
Table 1: Demographics of all the cases.
Feature Details
1 Number of case studied Total- 41 case
Males- 21, Females- 20
Mean age- 56 years (14 – 48 years)
2 Total lymph nodes studied 73 lymph nodes (SLN- 70, non-SLN- 3*) Mean- 1.7 SLN per case (1–4 SLN 
per case)
1 SLN- 16 cases
2 SLN- 17 cases
3 SLN- 4 cases
4 SLN- 4 cases
3 Pigmented lesions as indication for SLN biopsy Melanomas- 39
Atypical Spitzoid nevus- 1
Dysplastic nevus- 1
4 Location of primary pigmented lesion Head and neck (15), the trunk (11), the upper extremity (6), and the lower 
extremity (9).
5 Histological type of melanomas (known in 17 cases)¶ Superficial spreading- 11
Nodular- 5
Superficial spreading with nodular- 1
6 Breslow thickness of primary melanoma (known in 38 patients) Mean- 2.1 mm (range 0.7 to 8.9 mm)
*Case no. 23 (Table 2) had 5 lymph nodes (2 SLN and 3 non-SLN).
¶ In most cases, the biopsy of primary lesion was performed and interpreted at outside institutions.Page 3 of 9
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showed negative results with the intraoperative evalua-
tion of imprint smears.
An immunostained imprint smear was negative in one
case with a small focus of melanoma metastases (4 small
groups of 4–12 cells each in one small area) in one slice
of a single SLN. 2 SLNs showed unequivocal melanoma
metastases in rapid immunostained imprint smear (Table
2, case 3 & 12). In these 2 SLNs, metastases were not
detected by immunostained FPTS.
Two SLNs from 2 patients (Table 2, case 13 & 17) were
interpreted as indeterminate. Both of these SLNs were
negative for melanoma metastases by immunohistochem-
ical evaluation of FPTS. In 2 other cases, rare, singly scat-
Pathological evaluation of sentinel lymph nodes for melanoma metastasesFigure 1
Pathological evaluation of sentinel lymph nodes for melanoma metastases. Section number 2, 5, & 8- stained with HE; 4- immu-
nostained with 'MCW melanoma cocktail'; 6- negative control; 1, 3, 7, & 9- unstained sections on coated slides for immunos-
taining (but may be used for any stain). Number of slices of SLN shown (a,b,c) is for illustration only and would vary according 
to the size of the lymph node. (FPTS, formalin-fixed paraffin-embedded tissue sections; H&E, hematoxylin and eosin stain; 
immuno, immunohistochemistry)Page 4 of 9
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immunostaining with the cocktail were observed in both
immunostained imprint smears and permanent sections.
Discussion
In the current study, 8 out of 41 patients showed
melanoma metastases in lymph nodes employing immu-
Table 2: Results with rapid intraoperative immunocytochemical evaluation of imprint smears.
Serial No. No. of SLN per case SLN
IC SP FR4
1 2 B-,C- B-cn,C- N
2 1 A- A-cn N
3¶ 2 A1+,A2+,B- A1+,A2-,B- P
4 1 A- A-cn N
5 3 A-,B-,C- A-,B-cn,C- N
6 1 A- A- N
7 2 B-,C- B-,C- N
8 1 A- A- N
9 2 A-, C- A-, C- N
10 2 A-,C- A-cn,C- N
11* 4 A-,B-,C-,D- A+,B-,C-,D- P
12¶ 4 A-,B+,C+,D+ A-,B+,C+,D- P
13† 1 A(Intm) A- N
14 1 B+ B+ P
15 1 A- A- N
16 3 A+,B-,C- A+,B-,C- P
17† 2 A(Intm),B- A-,B- N
18 1 A- A- N
19 2 A-,B- A-,B- N
20 2 A1-, C+ A1-, C+ P
21 1 A- A- N
22 2 A-,B- A-,B- N
231 12 1A1-,1B+,1C-,D-,E- 1A1-,1B+,1C-,D-,E- P
24 1 A- A- N
25 2 A-,B- A-,B- N
26 2 A-,C- A-,C- N
27 1 B- B-cn N
28 1 A- A- N
29 1 A- A-cn N
30 1 A- A- N
312 4 A-,B-,C-,D- A-,B-,C-,D- N
32 2 A-,B- A-,B- N
33 1 A- A- N
34 4 A-,B-,C-,D- A-,B-,C-,D- N
35 3 A-,B-,C- A-,B-,C- N
363 1 A- A- N
37 2 A- A- N
38 2 B-,C- B-,C- N
39 2 A-,B- A-,B- N
40 3 A-,B-,D- A-,B-,D- N
41 2 A-,B+ A-,B+ P
*One false negative
†Two negative cases showed indeterminate results with IC
¶Two SLN were positive unequivocally with IC but negative by SP
1Only D&E were submitted as sentinel LN (A,B,C were submitted as non-SLN);
2Atypical Spitzoid nevus, recommended SLN biopsy;
3Dysplastic nevus, recommended SLN biopsy;
4Final results summarizing findings in all SLN in a particular case after immunostaining of permanent sections: total number of positive cases- 8 and 
negative cases- 33.
Abbreviations in alphabetical order: +, positive for melanoma metastases; -, negative for melanoma metastases; cn, capsular nevus; FR, final result; IC, 
rapid intraoperative immunocytochemistry; Intm, indeterminate for melanoma metastases; LN, sentinel and non-sentinel lymph nodes; N, negative; 
P, positive; SP, final result on permanent sections.Page 5 of 9
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showed metastases on imprint smears immunostained
with the 'MCW melanoma cocktail', potentially avoiding
a second surgery at a later date in 87.5% of these patients.
On a case basis, rapid intraoperative evaluation of imprint
smears with the 'MCW melanoma cocktail' yielded a sen-
sitivity of 89% and a specificity of 100%. On a lymph
node basis, sensitivity was 90% and specificity was 100%
(Table 2). These encouraging results are more promising
than alternative intraoperative approaches such as the fro-
zen-section alone [27], immunostaining frozen sections
with a cocktail of Melan- A, HMB-45, & tyrosinase [32], or
a morphological evaluation of imprint smears alone
[30,38] (Table 3).
Finding a positive SLN and completing the regional lym-
phadenectomy under the same anesthesia offers many
advantages. The extra cost for the second procedure was
predominantly the hospital cost. In this series with 41
patients, the extra cost (after deducting the cost for the
regional lymph node dissection procedure and adding the
cost for extended anesthesia) for 8 regional lymph node
dissections that needed to be performed at a later date was
$ 60,000 (average $ 7,500 per case). In comparison, the
cost of the intraoperative immunocytochemical evalua-
tion for 70 SLNs in all 41 cases ([CPT codes 88329 (for
intraoperative consult) + 88161 (for preparation and
processing of imprint smears for immunostaining) +
88342 (immunostaining and interpretation of immunos-
tained smears)] X 70) was only $33,233, resulting in
nearly 50% cost saving.
The most important benefit that cannot be quantified eas-
ily is the total avoidance of potential morbidity and mor-
tality associated with an additional surgery at a later date,
Cytomorphological spectrum of tumor cells (arrows) of melanoma metastases immunostained with 'MCW melanoma cocktail'Figure 2
Cytomorphological spectrum of tumor cells (arrows) of melanoma metastases immunostained with 'MCW melanoma cocktail'. 
The tumor cells were larger and showed high N/C ratio with non-granular cytoplasmic staining around the nuclei with usually 
clear nuclear details. The nuclear chromatin did not simulate the chromatin of lymphocytes in the background. The nucleoli 
may be prominent. The cell margins were well defined. (HE-FPTS, Hematoxylin-eosin stained formalin-fixed paraffin-embedded 
tissue sections; ICIS, immunocytochemical evaluation of imprint smears).Page 6 of 9
(page number not for citation purposes)
Diagnostic Pathology 2006, 1:32 http://www.diagnosticpathology.org/content/1/1/32improving patient care. Additionally, saving the patient
from a second visit to the surgical suite and its substantial
attendant costs along with a decreased number of office
visits (to reschedule the regional lymphadenectomy), less-
ens the inconvenience for the patient.
In cases with positive intraoperative SLN results, the dura-
tion of the surgical procedure would be lengthened for the
completion of the regional lymphadenectomy. Though it
demands flexibility in surgical scheduling, it may be
worth at most institutions.
As observed in one case, immunostained imprint smears
of SLN that turn out negative may be followed by positive
results after immunostaining the FPTS. This may require
the patient to return to the surgical suite for a lym-
phadenectomy at a later date. The patients should be
made aware of this possibility during preoperative consul-
tations.
Due to sampling benefits associated with imprint smears
[35], the immunostaining of imprint smears identified
metastases that may have been missed by studying immu-
nostained FPTS alone. This was observed in 2 cases in
which immunostained imprint smears of 2 SLNs were
unequivocally positive for melanoma metastases, but
immunostained FPTS were negative (Table 2, case 3 & 12).
Additional SLNs submitted in these 2 patients were posi-
tive with both immunostained imprint smears and FPTS,
further endorsing the true positive nature of finding.
One SLN from another case showed a micro-focus of
melanoma metastases in a single slice in immunostained
FPTS. However, the cells from this micro-focus with very
few tumor cells were not sampled by the imprint smears
leading to a false negative result. This underscores the sig-
nificance of chance factor associated with sampling in
general during the evaluation of SLN by any method.
Unequivocal positive result, obtained with either immu-
nostained imprint smears or with immunostained FPTS,
are significant. In cases where the intraoperative results
are positive, SLNs need not be evaluated further by immu-
nohistochemistry on FPTS. However, if the intraoperative
result is negative, immunohistochemical evaluation of
SLNs should go forward on FPTS. This would enhance the
sampling and increase the chances of detecting additional
melanoma metastases [35].
As a significant advantage, the cells of capsular nevi in 7
SLNs from 7 cases located in lymph node capsule and/or
septa as collections of spindle cells, did not exfoliate and
adhere to slides during the preparation of imprint smears.
As discussed previously, this is related to the cohesive
nature of benign nevus cells in capsular melanocytic nevi,
which would not exfoliate cells to the glass slide in con-
trast to poorly cohesive melanoma cells [33,35]. This
result in a distinct advantage for the immunocytochemi-
cal evaluation of imprint smears over other methods such
as RT-PCR, which may not have the benefit of a morpho-
logical correlation to avoid false positive results with
benign melanocytic capsular nevi (24).
Two SLNs from 2 patients, negative for melanoma metas-
tases by immunohistochemical evaluation of FPTS, were
interpreted as indeterminate in immunostained imprint
smears (Table 2 case 13 & 17). Retrospectively, the rare
doubtful cells observed in immunostained imprint
smears were consistent with mast cells which demon-
strated brown staining (even in respective negative con-
trols) due to endogenous peroxidase activity which could
not be blocked during the brief endogenous peroxidase
blocking step required by the rapid protocol [35]. Famili-
arity with morphological spectrum of immunostained
tumor cells (Figure 1) and other non-specifically stained
structures including mast cells in imprint smears prevents
indeterminate interpretation [35]. In two other cases, sin-
gly scattered cells showing cytoplasmic immunostaining
accompanied by small and inconspicuous nuclei were
observed. These rare single cells were also present in
immunostained permanent sections. The cytomorphol-
ogy was consistent with a benign interpretation in both
immunostained imprint smears and the permanent sec-
Table 3: Comparison of studies evaluating melanoma SLNs intraoperatively
Authors Intraoperative evaluation Sensitivity (%) Specificity (%)
Gibbs et al [20A] FS 43 100
Clary et al [20B] FS 56 100
Tanis et al [20C] FS 47 100
Stojadinovic [20] FS 59 100
Creager et al [21] IS 38 100
Eudy et al [23] FS with IHC 86 97
Current study ICIS 90 100
FPTS, formalin-fixed paraffin-embedded tissue section; FS, frozen section, ICIS, immunocytochemical evaluation of imprint smears with 'MCW 
melanoma cocktail' (mixture of Melan- A, MART- 1, & tyrosinase); , IHC, immunohistochemistry with cocktail of Melan- A, HMB-45, & tyrosinase); 
IS, imprint smear; SLNs, sentinel lymph nodes; MM, melanoma metastases.Page 7 of 9
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been reported in SLNs evaluated with MART-1 and Melan-
A [39].
For various reasons every laboratory may not be comfort-
able using cytological methods. However, objective
nature of interpreting immunostained tumor cells in
imprint smears would allow interpretation by most of the
pathology laboratories after a minor learning curve [35].
Imprint smears are less expensive and faster than frozen
sectioning without cryostat related tissue loss. They avoid
the frequently observed problems associated with the fro-
zen sectioning of fatty lymph nodes. If imprint smears are
made and the tissue is not frozen, it would prevent the
introduction of freezing artifacts and the associated inter-
pretation challenges on the permanent sections of such
frozen tissue.
Other approaches for the intraoperative evaluation of SLN
have demonstrated lower sensitivities (Table 3) but had
100% specificity, which is extremely important in order to
avoid un-indicated regional lymph-adenectomies [26-
32]. One study evaluating immunostaining of frozen sec-
tions demonstrated a slightly increased sensitivity than
when imprint smears or frozen sections alone were used
without immunostaining. However, the specificity was
less than 100% (Table 3). The immunostained frozen sec-
tions may show significant artifacts along with folds,
background staining, missing areas, and poor morphol-
ogy. As HMB45 is known to stain non-melanoma cells in
SLN [33,40-42], incorporation of HMB45 in the cocktail
used in this study may have contributed further to a reduc-
tion in the specificity [32,41,42]. As stated by the report-
ing authors of the study, a recent consensus group has
discouraged frozen-section examination of SLN [32].
In summary, imprint smears, rapidly immunostained
with the 'MCW melanoma cocktail' is a sensitive and spe-
cific method for the rapid intraoperative evaluation of
SLNs. If a SLN is found to be positive for melanoma
metastases in this way, the completion of a regional lym-
phadenectomy during the same surgical procedure for
SLN biopsy is feasible. Both negative and indeterminate
results should be regarded as negative when considering
intraoperative decision making for a regional lymph node
dissection during a given surgical procedure. In such
cases, the final decision for a regional lymph node dissec-
tion should be deferred until the final results with FPTS
are available.
Abbreviations
FPTS, formalin-fixed paraffin-embedded tissue section;
H&E, hematoxylin and eosin; SLN, sentinel lymph node;
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